Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an announcement.
Pharmaron Beijing Co., Ltd. has released its first quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which remains unaudited, provides insights into the company’s financial performance for the quarter, potentially impacting its operations and market positioning.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on providing research and development services to the pharmaceutical and biotech sectors.
YTD Price Performance: -10.53%
Average Trading Volume: 1,531
Technical Sentiment Signal: Buy
Current Market Cap: €4.52B
For an in-depth examination of 3759 stock, go to TipRanks’ Stock Analysis page.